Scilex Pharmaceuticals

Scilex Pharmaceuticals es propiedad de Sorrento Therapeutics.

Sorrento Therapeutics es una empresa que cotiza bajo el símbolo de cotización SRNE (US).

Ver el organigrama con sus 12 ejecutivos principales

Biografías más buscadas en Scilex Pharmaceuticals

• Jaisim Shah, Chief Executive Officer and Director
• Jay Chun, Director
• Laura Hamill, Director

Recientes movimientos de ejecutivos en Scilex Pharmaceuticals

• Elizabeth Czerepak, Executive Vice President, Chief Financial Officer and Chief Business Officer, ha dejado la empresa  (noticia publicada el 25 de septiembre de 2023).
• Stephen Ma que ha sido Chief Accounting Officer, ha ascendido a Chief Financial Officer  (noticia publicada el 25 de septiembre de 2023).
• Tien Lee, Director, ha dejado la empresa  (noticia publicada el 6 de septiembre de 2023).

Crear su alerta
para seguir los movimientos de los ejecutivos en Scilex Pharmaceuticals.

Sorrento Therapeutics tiene 1.861 competidores entre los que se incluyen Pfizer (Estados Unidos), Sanofi (Francia) y Johnson & Johnson (Estados Unidos).

Popular M&A news in Farmacia

• MedMen has filed for bankruptcy protection  (publicado el 28 de abril de 2024).
• AstraZeneca has announced the acquisition of Fusion Pharma  (publicado el 23 de marzo de 2024).
• AstraZeneca has announced the acquisition of Amolyt Pharma  (publicado el 19 de marzo de 2024).

Otros contactos sugeridos en el sector Farmacia

• Jean-Frédéric Paulsen - Executive Chairman of the Board en Ferring Pharmaceuticals
• Thierry Abribat - Chief Executive Officer en Amolyt Pharma
• Lucia Aleotti - Director en Menarini Group

Saber más sobre el sector Farmacia >

Últimos comunicados de prensa de Scilex Pharmaceuticals

• News & Events – Scilex Holding
• News & Events - Scilex Holding
• News - Scilex Holding
• Scilex Announces Addition of ZTlido® to Express Scripts National Formularies - Scilex Holding
• Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary Announces Expansion of Ztlido® Managed Care Coverage for Additional 33 Million Lives – SCILEX Pharmaceutical
• Scilex Holding Company, a Sorrento Company, Announces Complete Enrollment on Non-Opioid Injectable SP-102 (SEMDEXA™) Phase 3 Pivotal Trial C.L.E.A.R. Program For Sciatica Pain Management – SCILEX Pharmaceutical
• Scilex Holding, A Subsidiary of Sorrento, Has Received From FDA a sNDA Approval for Ztlido® Label Expansion – SCILEX Pharmaceutical
• Sorrento Therapeutics and Scilex Holding, a Majority Owned Subsidiary, Have Entered Into an Exclusive Licensing Term Sheet With Aardvark Therapeutics to Acquire Its ARD-301 For the Treatment of Chronic Pain, Fibromyalgia, and Chronic Long Haul Covid Syndr
• Scilex Holding Company, a Subsidiary of Sorrento Therapeutics, Announces Continuous Sales Growth in ZTlido® and Expects to Complete Enrollment on its SP-102 (SEMDEXA™) Phase 3 Pivotal Trial Program in 2020 – SCILEX Pharmaceutical
• Sorrento COVID-19 R&D October 13, 2020 Pipeline Call Details Released – SCILEX Pharmaceutical
• View more press releases Close

Redes sociales sobre Scilex Pharmaceuticals

• Scilex Pharmaceuticals en Wikipedia, Google News y Yahoo Finance
• Scilex Pharmaceuticals en LinkedIn, Twitter y YouTube

Contactar a través de e-mail con sus ejecutivos Jaisim Shah

Llame a Scilex Pharmaceuticals al +1 610...

Ver el organigrama

Register to receive your alert

Señalar un error